根據今天公布的兩項研究報告，晚期攝護腺癌病人除接受正規治療外，如增加使用一種新的抗荷爾蒙藥物，結果顯示可以減少死亡風險將近40%。
法新社報導，這種藥物是阿比特龍（abiraterone），楊森藥廠（Janssen Pharmaceuticals）有售，商品名為澤珂錠（Zytiga）。
其中一項研究發現，阿比特龍若與通常開給轉移性攝護腺癌患者服用的藥物潑尼松（prednisone）一起使用，死亡的風險減少了38%。
這項在美國臨床腫瘤學會（ASCO）年會上發布的報告又說，這種藥物也使得癌症惡化前的時間增加一倍有餘，由原本的14.8個月增至33個月。
這項臨床試驗包括34個國家的1200位病人，由2013年2月進行至2014年12月。
第二項臨床試驗涵蓋近2000位患者，結果發現在治療高風險的晚期攝護腺癌病人時，若除了標準的初步治療方法外再加上阿比特龍，也可以使相對死亡風險降低37%。
根據美國國家醫學圖書館（National Library of Medicine），比例高達92%的攝護腺癌病例能夠早期發現，也就是在腫瘤擴散到身體其他部分之前。不過，大約5%左右的患者被診斷出患病時，癌細胞已經擴散，治療前景欠佳。
https://udn.com/news/story/6812/2502635
Bloomberg – Jun 3, 2017
Johnson & Johnson's Zytiga helps men newly diagnosed with advanced prostate cancer live longer, according to new findings that could expand use of the medication. Men who received hormone therapy, the recommended first-time treatment, plus Zytiga …
Reuters – Jun 3, 2017
CHICAGO Adding Johnson & Johnson's Zytiga to standard hormone therapy reduced by nearly 40 percent the chance of death for men newly diagnosed with high-risk prostate cancer that had spread to other parts of the body, according to new trial results.
BioWorld Online – Jun 3, 2017
CHICAGO – Eagerly awaited data with abiraterone (Zytiga, Johnson & Johnson) in prostate cancer (PC) are “likely to change clinical practice pretty much overnight,” American Society of Clinical Oncology (ASCO) chief medical officer Richard Schilsky told …
FiercePharma – Jun 3, 2017
CHICAGO—Johnson & Johnson may soon be able to move prostate cancer med Zytiga into an earlier disease stage, thanks to game-changing new data that rolled out Saturday at the American Society of Clinical Oncology (ASCO) annual meeting. Zytiga, in …
The Pharma Letter (registration) – 18 hours ago
Top-line data from Janssen's eagerly-awaited clinical trial into Zytiga (abiraterone acetate) in combination with the standard of care for advanced prostate cancer have been released. The data show that the relative risk of death was lowered by 37%.
Seeking Alpha – Jun 3, 2017
Janssen announces data from the pivotal phase 3 LATITUDE clinical trial, which showed ZYTIGA (abiraterone acetate) plus prednisone, in combination with androgen deprivation therapy ("ADT"), demonstrated a significant improvement in overall survival and …
The Independent – Jun 3, 2017
Usually, abiraterone (sold commercially as Zytiga) is given to men who have stopped responding to ADT but the study found that giving it much earlier – and in combination with ADT – had much stronger benefits. Adding abiraterone to ADT reduced the risk …
Endpoints News – Jun 3, 2017
CHICAGO — J&J will be looking to expand its blockbuster market for Zytiga (abiraterone) after posting stellar data at ASCO showing that the drug combined with standard hormone therapy registered a major improvement in progression-free survival among …
Normangee Star – 17 hours ago
Combined therapy with abiraterone acetate/prednisone plus androgen deprivation therapy (ADT) significantly improved overall survival and radiographic progression-free survival (PFS) among men with metastatic hormone-naive prostate cancer compared …
pppFocus – Jun 3, 2017
J&J will be looking to expand its blockbuster market for Zytiga (abiraterone) after posting stellar data at ASCO showing that the drug combined with standard …
MedPage Today – Jun 3, 2017
CHICAGO — Dramatic results in two clinical trials are persuading experts here that an androgen-suppressing drug should be used earlier in men with prostate …
BBC News – Jun 3, 2017
Abiraterone, also known as Zytiga, is a hormone therapy. Unlike chemotherapy which kills the cancerous cells, it stops more testosterone from reaching the prostate gland to stifle the tumour's growth. The trial involved almost 2,000 patients. Half the …
AppsforPCdaily – 8 hours ago
Men who received hormone therapy, the recommended first-time treatment, plus Zytiga were about one-third less likely to die during two studies than those who got standard treatment alone, according to research presented Saturday at the American Society …
